在老年人群中治疗皮肤疾病的口服皮质类固醇:尽量减少潜在的不良影响
Kennedy Sparling1, Daniel C Butler2
1University of Arizona, College of Medicine - Phoenix, 475 N 5th St, Phoenix, AZ, 85004, USA. ksparling@arizona.edu.
Drugs & aging
|September 16, 2024
概括
口服皮质类固醇是重要的抗炎药物,但对老年人来说存在重大风险. 本综述详细介绍了这种人群的不良影响和安全管理策略.
科学领域:
- 皮肤病学 皮肤病学
- 老年病的医生 老年病的医生
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮质类固醇是必不可少的抗炎和免疫调节剂,用于各种医学领域,包括皮肤病学.
- 尽管有治疗效益,但系统性皮质类固醇使用,特别是在老年人中,与严重的不良影响有关.
- 老年人代表了一个易受伤害的人群,容易受到皮质类固醇诱导并发症的风险增加.
研究的目的:
- 审查与老年人口服皮质类固醇治疗相关的广泛不良反应.
- 为预防,监测和管理这些不良影响提供基于证据的战略.
- 加强口服皮质类固醇在老年人皮肤病的安全和有效使用.
主要方法:
- 关于口服皮质类固醇副作用研究的综合文献综述.
- 对老年人群特有的风险因素和管理策略的分析.
- 综合目前关于皮质类固醇诱导并发症及其缓解的证据.
主要成果:
- 系统性皮质类固醇与许多不良影响有关,包括免疫抑制,胃肠道问题,代谢障碍 (高血糖症,胰岛素抵抗,体重增加),心血管并发症,眼睛问题,骨密度下降 (骨质疏松症,骨髓缩),肌肉疲弱,原合成受损,精神症状和上腺抑制.
- 老年人患上这些不良反应的风险较高,原因是与衰老相关的生理变化.
- 有效的管理包括量身定制的剂量和持续时间,警的监测和积极的预防性干预.
结论:
- 口服皮质类固醇虽然有效,但需要仔细考虑其风险,特别是在老年患者中.
- 实施定制的管理计划,包括剂量调整和定期监测,对于尽量减少不良事件至关重要.
- 通过个性化策略优化皮质类固醇治疗可以改善炎症性皮肤病患者的治疗结果和生活质量.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
228
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
228
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs Used in Lower Respiratory Disorders: Overview
362
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
362


